文献速递胃肠动力与功能性疾病

粪菌移植治疗肠易激综合征:随机双盲安慰剂对照研究

Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study.
PubMed 文献 · Gut · 2019-12-18

该随机双盲安慰剂对照研究将165例肠易激综合征患者按1:1:1分为安慰剂组、30g粪菌移植组和60g粪菌移植组,经胃镜给予来自单一健康供体的冷冻粪菌。结果显示,三组应答率分别为23.6%、76.9%(p<0.0001)和89.1%(p<0.0001),且粪菌移植组疲劳和生活质量显著改善,肠道菌群谱也显著变化,不良反应为轻度自限性胃肠道症状。

要点

  • 粪菌移植对肠易激综合征有效,且应答率随剂量增加而升高。
  • 使用菌群失调指数正常且具有有利特定微生物特征的定义明确的供体是成功关键。
  • 粪菌移植不良反应为轻度自限性胃肠道症状。

核心结论

  • 粪菌移植是肠易激综合征的有效治疗方法。
  • 使用菌群失调指数正常且具有有利特定微生物特征的定义明确的供体对粪菌移植成功至关重要。
  • 粪菌移植的应答随剂量增加而增加。

研究设计与样本

  • 随机、双盲、安慰剂对照研究,共随机165例肠易激综合征患者。
  • 患者按1:1:1比例随机分配至安慰剂(自身粪便)、30g粪菌移植或60g粪菌移植组。
  • 粪菌移植材料来自一名健康且特征明确的供体,经冷冻后通过胃镜给药。

主要发现

  • 安慰剂组、30g粪菌移植组和60g粪菌移植组的应答率分别为23.6%、76.9%(p<0.0001)和89.1%(p<0.0001)。
  • 接受粪菌移植的患者疲劳和生活质量显著改善。
  • 接受粪菌移植的组肠道细菌谱也显著变化。
  • 粪菌移植的不良事件为轻度自限性胃肠道症状。

关键数值与推荐

  • 主要结局为粪菌移植后3个月肠易激综合征症状减轻(应答),应答定义为总肠易激综合征症状评分下降50分或以上。
  • 次要结局为粪菌移植后1个月菌群失调指数降低及通过16S rRNA基因测序分析的肠道细菌谱变化。

临床怎么用

  • 对于肠易激综合征患者,可考虑粪菌移植治疗,且较高剂量(60g)可能应答率更高。
  • 实施粪菌移植时应选用菌群失调指数正常且具有有利特定微生物特征的定义明确的供体。
  • 粪菌移植后需关注轻度自限性胃肠道症状等不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Faecal microbiota transplantation (FMT) from healthy donors to patients with irritable bowel syndrome (IBS) has been attempted in two previous double-blind, placebo-controlled studies. While one of those studies found improvement of the IBS symptoms, the other found no effect. The present study was conducted to clarify these contradictory findings. DESIGN: This randomised, double-blind, placebo-controlled study randomised 165 patients with IBS to placebo (own faeces), 30 g FMT or 60 g FMT at a ratio of 1:1:1. The material for FMT was obtained from one healthy, well-characterised donor, frozen and administered via gastroscope. The primary outcome was a reduction in the IBS symptoms at 3 months after FMT (response). A response was defined as a decrease of 50 or more points in the total IBS symptom score. The secondary outcome was a reduction in the dysbiosis index (DI) and a change in the intestinal bacterial profile, analysed by 16S rRNA gene sequencing, at 1 month following FMT. RESULTS: Responses occurred in 23.6%, 76.9% (p<0.0001) and 89.1% (p<00.0001) of the patients who received placebo, 30 g FMT and 60 g FMT, respectively. These were accompanied by significant improvements in fatigue and the quality of life in patients who received FMT. The intestinal bacterial profiles changed also significantly in the groups received FMT. The FMT adverse events were mild self-limiting gastrointestinal symptoms. CONCLUSIONS: FMT is an effective treatment for patients with IBS. Utilising a well-defined donor with a normal DI and favourable specific microbial signature is essential for successful FMT. The response to FMT increases with the dose. Trial registration www.clinicaltrials.gov (NCT03822299) and www.cristin.no (ID657402).

来源:Gut,查看原文。版权归原作者所有。

引用

  1. El-Salhy M, Hatlebakk JG, Gilja OH, et al. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut. 2019. PMID: 31852769. doi:10.1136/gutjnl-2019-319630

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。